One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [177Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting

被引：0

作者：

Basu, Sandip ^{[1
,2
]}

Chakraborty, Sudipta ^{[2
,3
]}

Parghane, Rahul, V ^{[1
,2
]}

Kamaldeep ^{[2
,4
]}

Ranade, Rohit ^{[1
,2
]}

Thapa, Pradeep ^{[1
,2
]}

Asopa, Ramesh, V ^{[1
,2
]}

Sonawane, Geeta ^{[1
,2
]}

Nabar, Swapna ^{[1
,2
]}

Shimpi, Hemant ^{[1
,2
]}

Chandak, Ashok ^{[1
,2
]}

Vimalnath, K. V. ^{[3
]}

Ostwal, Vikas ^{[2
,5
]}

Ramaswamy, Anant ^{[2
,5
]}

Bhandare, Manish ^{[2
,6
]}

Chaudhari, Vikram ^{[2
,6
]}

Shrikhande, Shailesh, V ^{[2
,6
]}

Sirohi, Bhawna ^{[5
,7
]}

Dash, Ashutosh ^{[2
,3
]}

Banerje, Sharmila ^{[1
,2
]}

机构：

[1] Bhabha Atom Res Ctr, Radiat Med Ctr, Jerbai Wadia Rd, Mumbai 400012, Maharashtra, India

[2] Homi Bhabha Natl Inst, Mumbai, Maharashtra, India

[3] BARC, Radiopharmaceut Div, Mumbai, Maharashtra, India

[4] Bhabha Atom Res Ctr, Hlth Phys Div, Mumbai, Maharashtra, India

[5] Tata Mem Hosp, Dept Med Oncol, Mumbai, Maharashtra, India

[6] Tata Mem Hosp, Gastrointestinal & Hepatopancreato Biliary Serv, Dept Surg Oncol, Mumbai, Maharashtra, India

[7] Apollo Proton Canc Ctr, Chennai, Tamil Nadu, India

来源：

AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 10卷 / 04期

关键词：

Neuroendocrine neoplasms (NENs); neuroendocrine tumor; peptide receptor radionuclide (PRRT); somatostatin receptor (SSTR); Lu-177]Lu-DOTATATE; Y-90]Y-DOTATATE; Direct' neutron activation route; (177)Lutetium; chemo-PRRT; duo-PRRT; TUMOR PROLIFERATION INDEX; PULMONARY NEUROENDOCRINE TUMORS; CARRIER-ADDED LU-177; CHEMORADIONUCLIDE THERAPY; INDIVIDUALIZED DOSIMETRY; RADIATION SAFETY; RESEARCH REACTOR; LU-177-DOTATATE; LU-177-OCTREOTATE; PRRT;

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The present treatise chronicles one decade of experience pertaining to clinical PRRT services in a large-volume tertiary cancer care centre in India delivering over 4,000 therapies, an exemplar of successful PRRT programme employing indigenous (177)Lutetium production and resources. For the purpose of systematic discussion, we have sub-divided the communication into 3 specific parts: (a) Radiopharmaceutical aspects that describes Lu-177-tetium production through 'Direct' Neutron Activation Route and the subsequent radiolabeling procedures, (b) The specific clinical nuances and finer learning points (apart from the routine standard procedure) based upon clinical experience and how it has undergone practice evolution in our setting and (c) Dosimetry results with this indigenous product and radiation safety/health physics aspects involved in PRRT services. Initiated in 2010 at our centre, the PRRT programme is a perfect example of affordable quality health care delivery, with indigenous production of the radionuclide (Lu-177) in the reactor and subsequent radiolabeling of the radiopharmaceutical ([Lu-177]Lu-DOTATATE) at the hospital radiopharmacy unit of the centre, which enabled catering to the needs of a large number of patients of progressive, metastatic and advanced Neuroendocrine Neoplasms (NENs) and related malignancies.

引用

页码：178 / 211

页数：34

共 2 条

[1] On the practical aspects of large-scale production of 177Lu for peptide receptor radionuclide therapy using direct neutron activation of 176Lu in a medium flux research reactor: the Indian experience
Sudipta Chakraborty
K. V. Vimalnath
Sharad P. Lohar
Priyalata Shetty
Ashutosh Dash
Journal of Radioanalytical and Nuclear Chemistry, 2014, 302 : 233 - 243
[2] On the practical aspects of large-scale production of 177Lu for peptide receptor radionuclide therapy using direct neutron activation of 176Lu in a medium flux research reactor: the Indian experience
Chakraborty, Sudipta
Vimalnath, K. V.
Lohar, Sharad P.
Shetty, Priyalata
Dash, Ashutosh
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2014, 302 (01) : 233 - 243

← 1 →